The Mian Lab is exploring the genetic and epigenetic mechanisms underlying lethal cancers of the genitourinary tract with the goal of translating discovery into novel therapies. Our approach couples translational research to clinical investigation in GU malignancies at Cleveland Clinic's Lerner Research Institute. We are developing powerful tools for identifying predictive and prognostic biomarkers as well as for therapeutic target discovery.
Our mission is to reduce the burden of prostate and bladder cancer through fundamental discovery and to improve the lives of cancer patients.
Dr. Mian is a radiation oncologist and physician scientist at Cleveland Clinic's Lerner Research Institute. His research interests center around the genetics and epigenetics of bladder and prostate cancer.
Shinjini studies genetic and epigenetic mechanisms through which androgen receptor signaling influences DNA damage response and the resulting effects on therapeutic resistance in prostate cancer.
Anthony, a medical doctor and talented scientist, is working on regulation in breast and prostate cancer as a postdoctoral research fellow in our lab.
Jarrell is a senior at Case Western Reserve University. He is studying neuroendocrine bladder cancer as a part of his senior project.
Anya is a staff scientist who oversees projects and mentors rotating students and works closely with our postdoctoral fellows.
Andrew is a recent graduate of Ohio State University and, in addition to supporting various other projects, he is studying the role of circulating biomarkers in cell free DNA in patient risk stratification for a variety of cancers.
Monica is a 2nd year CCLCM student studying bladder cancer organ preservation approaches biomarkers and response to immunotherapy using informatics and genomics approaches.
Pari is a pediatric hematology-oncology fellow profiling the epigenetics of rhabdomyosarcoma in the lab as a part of her research rotation.
Claudia is a 1st year CCLCM student studying neuroendocrine transdifferentiation.
We are exploring the genetic and epigenetic mechanisms underlying lethal cancers of the genitourinary tract with the goal of translating discovery in to novel therapies. Our approach couples translational research to clinical investigation in GU malignancies at Cleveland Clinic's Lerner Research Institute. We are developing powerful tools for identifying predictive and prognostic biomarkers as well as for therapeutic target discovery. The mission of our lab is to reduce the burden of prostate and bladder cancer through fundamental discovery and to improve the lives of cancer patients.
Selected Publications (2015-2020)
Drs. Mian, Gupta and Hwang—a multi-disciplinary team of researchers and clinicians—will look for ways to optimize immune checkpoint inhibitor therapy, including testing novel combinatory treatments and identifying predictive biomarkers of treatment response.
A Postdoctoral fellow position is available immediately in the Mian Laboratory, in the Department of Translational Hematology and Oncology Research (THOR) at the Cleveland Clinic’s Lerner Research Institute in Cleveland, OH.
An fully funded position awaits a fellow looking to pursue a dynamic career in translational biomedical research! Our lab at the Cleveland Clinic studies epigenetic, metabolic, and endocrine determinants of response to DNA damage in a variety of cancers. The work involves characterization of innovative preclinical models using genome editing and molecular analysis methods. Clinical samples are readily available for validation studies. The position offers excellent opportunities for publication, career development and advancement. Candidates will join a stimulating academic environment within the Genitourinary Malignancies Research Center of the Lerner Research Institute.
Highly motivated individuals with a strong background and interest in translational cancer research are encouraged to apply. Applicants must be recent Ph.D. or M.D./Ph.D. graduates in cell biology, molecular biology, cancer biology, molecular genetics, developmental biology or related fields. Prior experience in culture of human primary and cancer cell lines, molecular biology, as well as a track record of peer-reviewed publications is required. Individuals with additional experience in genome editing, mouse work or bioinformatics, are strongly encouraged to apply.
Interested applicants should send a CV, a cover letter/statement that describes career goals, and 3 references to Dr. Omar Mian (miano@ccf.org).